The Medicare GLP-1 Bridge, an 18-month pilot launched in July 2026, sets a $50 monthly copay for Wegovy, the Zepbound KwikPen and the oral drug Foundayo. Zepbound previously ran to $750 a month.

To qualify you must be in Medicare Part D and have a BMI of 35 or above, or 27 to 34 with a condition such as prediabetes or cardiovascular disease.

About 5.9 million Medicare enrollees are excluded, and the reason is the part that stops people reading past the headline: they are excluded because they have an FDA-approved condition for a GLP-1, such as type 2 diabetes or moderate to severe obstructive sleep apnea. Those patients are routed to Part D plans with copays of $200 to $600 a month.

The logic, which is not an error

It looks perverse and it follows from how the programme was built.

Juliette Cubanski, who directs Medicare policy at KFF, gives the design intent: "The Bridge program was designed to target those people who can't get GLP-1 coverage through Part D but would benefit from taking one for weight loss."

Part D has historically not covered these drugs when prescribed purely for weight loss. It does cover them when prescribed for an approved medical indication. The Bridge was built to fill the first gap, so eligibility was drawn around people with no other route. Having a covered diagnosis means you have a route, and therefore fall outside the programme designed for people who do not.

The gap the design misses is between coverage and cost. As Dr Taylor Lacy, a primary care physician, puts it: "'Coverage' doesn't always mean 'affordable.'" A patient with a $200 to $600 monthly copay is covered and may still not fill the prescription.

What it looks like to one person

Jeff La Marca, 68, of Basking Ridge, New Jersey, has a BMI of 42, a history of quadruple heart bypass, prediabetes, stroke risk and severe obstructive sleep apnea.

He meets the weight-based criteria comfortably. His application was denied because of the sleep apnea diagnosis.

One case is not evidence of how a programme performs overall, and we report it as an illustration of the rule rather than as a measurement of its frequency. What it does show is that the exclusion binds on exactly the patients whose medical case is strongest.

The arithmetic Medicare is working with

The programme is projected to cost $3.3 billion if 25 percent of an estimated 3.8 million eligible beneficiaries enrol for the full 18 months, and $10 billion at 75 percent.

Work those back. Twenty-five percent of 3.8 million is 950,000 people over 18 months, or 17.1 million member-months, which puts the cost at roughly $193 per member-month. The 75 percent case gives about $195. So Medicare is carrying somewhere near $195 a month per patient on top of the $50 the patient pays, which implies a net negotiated price in the region of $245 against a $750 list.

That is the number the pilot is really testing, and the reason it is a pilot: a programme that costs $3.3 billion at a quarter take-up costs $10 billion at three quarters, and the difference is entirely how many people show up.

The Centers for Medicare and Medicaid Services says the pilot is working as intended. Spokesman Timothy Foster: "This has allowed thousands of eligible beneficiaries to access GLP-1 medications for weight loss at pharmacies nationwide."

For anyone in this position

Two practical points, and neither is advice about treatment.

The exclusion turns on a diagnosis code rather than on your weight or your risk, so the question to ask a prescriber is which indication a claim is being submitted under. And Part D plan design varies considerably between plans and between years, so a copay of $200 to $600 is a range across plans rather than a fixed price, which makes the annual enrolment window the point at which the number can actually change.

This story explains a public programme and is not medical or financial advice.